Verona Pharma, which recently announced that a Phase 3 trial of its nebulized ensifentrine for the treatment of COPD met its primary endpoint, has announced the appointments of Matthew Casbon as VP of Sales, Marketing, and Training and Matthew Rysavy as VP of Market Access and Trade in preparation for potential commercialization.
Casbon was most recently Chief Business Officer at Target RWE and previously served briefly as Circassia Pharmaceuticals Senior VP of Global Strategic Marketing and Training after having served as Circassia’s VP of Global Strategic Marketing. His past experience also includes business and marketing positions KemPharm, Chimerix, Salix Pharmaceuticals, Abbott Laboratories, and Solvay Pharmaceuticals.
Rysavy was most recently Executive Director of Market Access and Trade at BioDelivery Sciences International and previously held positions at US World Meds/HEMA Biologics, BioDelivery Sciences, Orexo, and Salix.
Verona Senior VP of Commercial Chris Martin commented, “We are very pleased to welcome Mr. Casbon and Mr. Rysavy to Verona Pharma at this exciting time of company growth and progression. Last week, we reported positive Phase 3 results from our ENHANCE-2 trial evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”). We expect to report the results from our ongoing Phase 3 trial, ENHANCE-1, around the end of the year. If similar positive results are achieved, we plan to submit a New Drug Application to the US Food and Drug Administration in the first half of 2023. The leadership skills and wealth of experience of Mr. Casbon and Mr. Rysavy in launching novel therapeutics will be very valuable as we refine our go to market strategy for ensifentrine and begin our commercialization preparations.”
Read the Verona Pharma press release.
